Treatment with trastuzumab showed significantly improved clinical outcomes in patients; however, HER2-positive gastric cancer patients exhibited reduced sensitivity to trastuzumab than the breast cancer patients [2, 3]. Here, ERBB2 is linked to breast carcinoma.